Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
ST. LOUIS, Feb. 08, 2016 -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2015 fourth quarter and full year ended December 31, 2015 on Monday, February 22, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the Company’s results and corporate developments.
| What: | Stereotaxis fourth quarter and full year 2015 financial results conference call | ||||||
| When: | Monday, February 22nd at 4:30 p.m. Eastern Time (1:30 p.m. PT) | ||||||
| Dial In Number: | To access the live call, dial 888-417-8465 (US and Canada) or 719-325-2329 (International) and give the participant pass code 4685179. | ||||||
| Webcast: | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at www.stereotaxis.com | ||||||
| Call Replay: | A replay of the call will be available approximately one hour following the end of the call through 7:30 p.m. ET on February 29, 2016. | ||||||
| Replay Numbers: | 888-203-1112 (US and Canada) | ||||||
| 719-457-0820 (International) | |||||||
| Replay passcode: 4685179 | |||||||
About Stereotaxis
Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' core Epoch® Solution includes the Niobe® ES remote magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management systems, and the Vdrive® robotic navigation system and consumables.
The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Canada, China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator, V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter advancement system have received clearance in the United States, Canada, and the European Union. For more information, please visit www.stereotaxis.com.
Press Contact: Martin Stammer Chief Financial Officer 314-678-6155 Investor Contact: Todd Kehrli / Jim Byers MKR Group, Inc. 323-468-2300 [email protected]
